Randomized, double-blind trial

Patient population (N = 5395)

  • Confirmed symptomatic proximal DVT or PE (with or
    without DVT)
  • ≥18 years of age

Primary efficacy outcome

  • Composite of symptomatic recurrent VTE or death
    related to VTE

Primary safety outcome

  • Major bleeding*
  • Key secondary safety outcome
  • Composite of major or CRNM bleeding†
Apixaban
10 mg BID, oral
Apixaban
5 mg BID, oral
Enoxaparin SC
1 mg/kg Q12H until INR
≥2.0
Warfarin QD, oral
INR 2.0-3.0
358 centers
28 countries

Limitations

Randomized controlled trials include patients and participating centers
that may not be entirely representative of the real-world seting

7 days
6 months
≥5 days
6 months
n = 2691
n = 2704
R